文献速递免疫规划妇幼与学校卫生

婴儿无细胞百日咳疫苗的剂量依赖性有效性:一项基于人群的病例对照研究

Dose-dependent effectiveness of acellular pertussis vaccine in infants: A population-based case-control study.
PubMed 文献 · Vaccine · 2019-12-05

研究在瑞士开展基于人群的回顾性病例对照研究,比较2.5月龄至2岁因百日咳住院儿童与2岁随机对照儿童的免疫数据,发现婴儿「3+1」基础免疫中,针对百日咳住院的疫苗有效性随剂次增加而显著上升,第1至第4剂后分别为42.1%、83.9%、98.2%和100%。

要点

  • 「3+1」基础免疫中,针对百日咳住院的疫苗有效性随剂次增加而显著上升。
  • 第1、2、3、4剂后疫苗有效性分别为42.1%、83.9%、98.2%、100%。
  • 无细胞百日咳疫苗继续显示对婴幼儿百日咳住院的保护作用。

核心结论

  • 无细胞百日咳疫苗继续显示对婴幼儿百日咳住院的保护作用。
  • 结合孕妇和家庭接触者免疫接种的推进,及时启动免疫接种可更好地控制婴幼儿重症百日咳。

研究设计与样本

  • 基于人群的回顾性病例对照研究,比较2.5月龄至2岁因百日咳住院且居住在瑞士的儿童与居住在瑞士的2岁随机对照样本儿童的免疫数据。
  • 疫苗有效性定义为按无细胞百日咳疫苗剂次避免住院的百分比,计算为1-感染率比(IRR)×100。

主要发现

  • 婴儿「3+1」基础免疫中,针对百日咳住院的疫苗有效性随每剂次显著上升:第1剂后42.1%(95%CI:11.3-62.6),第2剂后83.9%(95%CI:70.2-92.1),第3剂后98.2%(95%CI:96.1-99.3),第4剂后100%(95%CI:97.9-100)。

临床怎么用

  • 原文结论指出,结合孕妇和家庭接触者免疫接种的推进,及时启动免疫接种可更好地控制婴幼儿重症百日咳。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pertussis is a vaccine-preventable disease which is most severe in young infants. More than two decades after the introduction of acelluar pertussis vaccines (aPV) in national immunization programs in many countries worldwide, a resurgence of pertussis has been recognized. Suboptimal effectiveness of aPV has been blamed as one major reason but only few studies have evaluated dose-dependent vaccine effectiveness (VE) provided by aPV in current practice. METHODS: We performed a population-based retrospective case-control study by comparing pertussis immunization data of children 2.5 months to 2 years of age hospitalized for pertussis and residing in Switzerland with immunization data of a random control sample of children aged 2 years and residing in Switzerland. VE was defined as the percentage of hospitalizations avoided by number of aPV doses. It was calculated as 1-infection rate ratio (IRR)*100. IRR was calculated by dividing infection rates of vaccinated children and infection rates of unvaccinated children. To get dose specific VE,infection rates were stratified by number doses received. RESULTS: VE against hospitalization due to pertussis increased significantly with each consecutive aPV dose in a "3 + 1" primary course in infants: 42.1% (95% CI: 11.3-62.6), 83.9% (70.2-92.1), 98.2% (96.1-99.3), and 100% (97.9-100) after the 1st, 2nd, 3rd, and 4th dose, respectively. CONCLUSION: Acellular pertussis vaccines continue to demonstrate protection against hospitalization due to pertussis in infants and young children. Therefore, together with advancing immunization of pregnant women and household contacts, better control of severe pertussis in young infants can be achieved by timely initiation of immunization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mack I, Erlanger TE, Lang P, et al. Dose-dependent effectiveness of acellular pertussis vaccine in infants: A population-based case-control study. Vaccine. 2019. PMID: 31813648. doi:10.1016/j.vaccine.2019.11.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。